First Half operating verticals revenues of €571m, confirming return to topline growth, driven by Eutelsat GEO business and inclusion of OneWeb LEO business in the Second Quarter
Continued rise.
13.02.2024 - Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus .
Kaufman & Broad SA: ANNUAL RESULTS 2023 -4- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Kaufman & Broad SA
Kaufman & Broad SA: ANNUAL RESULTS 2023 31-Jan-2024 / 18:38 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely.
Kaufman & Broad SA: ANNUAL RESULTS 2023 -3- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.